MedTrace Logo

Comparison of [68Ga]GaFAPI-46 PET/CT and [18F]FDG PET/CT Findings in Breast Carcinoma

NCT05339113 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-06-24

No results posted yet for this study

Summary

The aim of this study is to compare the diagnostic performance of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT in primary and metastatic lesions of breast cancer and to reveal the best diagnostic imaging time of 68Ga-FAPI-46 PET/CT.

Conditions

  • Breast Neoplasms
  • Positron Emission Tomography
  • Fibroblast Activation Protein Inhibitor
  • Fluorodeoxyglucose F18

Interventions

DIAGNOSTIC_TEST

68Ga-FAPI-46 PET/CT

Patients are scanned 10 minute, 30 minute and 1 hour after 68Ga-FAPI-46 as well as one hour 18-FDG injection within 2-3 days interval.

Sponsors & Collaborators

  • SOFIE INC

    collaborator UNKNOWN

  • The National Center of Oncology, Azerbaijan

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-04
Primary Completion
2022-09-30
Completion
2022-12-31

Countries

  • Azerbaijan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05339113 on ClinicalTrials.gov